Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring

Abstract Time in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability of treatment with sulfonylureas (SUs) in type 2 diabetes mellitus (T2DM) with well-controlled glucose level (TIR > 70%). The study subjec...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fumi Uemura, Yosuke Okada, Keiichi Torimoto, Yoshiya Tanaka
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/bb2b320b7b704bd1be53a008be945655
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bb2b320b7b704bd1be53a008be945655
record_format	dspace
spelling	oai:doaj.org-article:bb2b320b7b704bd1be53a008be9456552021-12-02T15:54:09ZEnlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring10.1038/s41598-021-83999-z2045-2322https://doaj.org/article/bb2b320b7b704bd1be53a008be9456552021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83999-zhttps://doaj.org/toc/2045-2322Abstract Time in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability of treatment with sulfonylureas (SUs) in type 2 diabetes mellitus (T2DM) with well-controlled glucose level (TIR > 70%). The study subjects were 123 patients selected T2DM who underwent CGM more than 24 h on admission without changing treatment. The primary endpoint was the difference in glycemic variability, while the secondary endpoint was the difference in time below range < 54 mg/dL; TBR < 54, between the SU (n = 63) and non-SU (n = 60) groups. The standard deviation, percentage coefficient of variation (%CV), and maximum glucose level were higher in the SU group than in the non-SU group, and TBR < 54 was longer in the high-dose SU patients. SU treatment was identified as a significant factor that affected %CV (β: 2.678, p = 0.034). High-dose SU use contributed to prolonged TBR < 54 (β: 0.487, p = 0.028). Our study identified enlarged glycemic variability in sulfonylurea-treated well-controlled T2DM patients and high-dose SU use was associated with TBR < 54. The results highlight the need for careful adjustment of the SU dose, irrespective of glycated hemoglobin level or TIR value.Fumi UemuraYosuke OkadaKeiichi TorimotoYoshiya TanakaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Fumi Uemura Yosuke Okada Keiichi Torimoto Yoshiya Tanaka Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring
description	Abstract Time in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability of treatment with sulfonylureas (SUs) in type 2 diabetes mellitus (T2DM) with well-controlled glucose level (TIR > 70%). The study subjects were 123 patients selected T2DM who underwent CGM more than 24 h on admission without changing treatment. The primary endpoint was the difference in glycemic variability, while the secondary endpoint was the difference in time below range < 54 mg/dL; TBR < 54, between the SU (n = 63) and non-SU (n = 60) groups. The standard deviation, percentage coefficient of variation (%CV), and maximum glucose level were higher in the SU group than in the non-SU group, and TBR < 54 was longer in the high-dose SU patients. SU treatment was identified as a significant factor that affected %CV (β: 2.678, p = 0.034). High-dose SU use contributed to prolonged TBR < 54 (β: 0.487, p = 0.028). Our study identified enlarged glycemic variability in sulfonylurea-treated well-controlled T2DM patients and high-dose SU use was associated with TBR < 54. The results highlight the need for careful adjustment of the SU dose, irrespective of glycated hemoglobin level or TIR value.
format	article
author	Fumi Uemura Yosuke Okada Keiichi Torimoto Yoshiya Tanaka
author_facet	Fumi Uemura Yosuke Okada Keiichi Torimoto Yoshiya Tanaka
author_sort	Fumi Uemura
title	Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring
title_short	Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring
title_full	Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring
title_fullStr	Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring
title_full_unstemmed	Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring
title_sort	enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/bb2b320b7b704bd1be53a008be945655
work_keys_str_mv	AT fumiuemura enlargedglycemicvariabilityinsulfonylureatreatedwellcontrolledtype2diabeticsidentifiedusingcontinuousglucosemonitoring AT yosukeokada enlargedglycemicvariabilityinsulfonylureatreatedwellcontrolledtype2diabeticsidentifiedusingcontinuousglucosemonitoring AT keiichitorimoto enlargedglycemicvariabilityinsulfonylureatreatedwellcontrolledtype2diabeticsidentifiedusingcontinuousglucosemonitoring AT yoshiyatanaka enlargedglycemicvariabilityinsulfonylureatreatedwellcontrolledtype2diabeticsidentifiedusingcontinuousglucosemonitoring
_version_	1718385472187662336

Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring

Ejemplares similares